Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
Status:
Completed
Trial end date:
2017-07-13
Target enrollment:
Participant gender:
Summary
This is a clinical trial including non-surgical patients, 70 years of age or older, with
renal impairment requiring pharmacological venous thromboembolism prevention during
hospitalization. Patients are randomized to receive either 20 mg or 30mg of enoxaparin. Both
dosing regimens of enoxaparin have been approved for thromboprophylaxis in impaired kidney
function in different countries. Therefore, this study aims to evaluate the efficacy and
safety of enoxaparin 20mg versus 30mg subcutaneously daily by comparing anti-xa levels,
thrombosis and bleeding events.